Skip to Main Content

Paper Details

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Clin Cancer Res
3
2022
-infiltrating lymphocyte, AA, PD-L1, TNBC, patients, sTIL, stromal tumor, triple-negative breast cancer, tumor, women
Author NameAffiliation
David L RimmYale School of Medicine
Lajos PusztaiYale School of Medicine
  • 1 - 2

Datasets

Release 1.2